1Miyazawa K, Shimomura T, Kitamura N. Activation of hepatocyte growth factor in the injured tissues is mediated by hepatocyte growth factor activator. J Biol Chem, 1996, 271: 3615-3618.
2Naldini L, Vigna E, Bardelli A, et al. Biological activation of pro HGF(hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction. J Biol Chem, 1995, 270: 603-611.
3Matsumoto K, Nakamura T. Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. Kidney Int, 2001, 59 (6): 2023-2038.
4Schaeper U, Gehring NH, Fuchs KP, et al. Coupling of gab1 to c-met , grb2, and shp2 mediates biological responses. J Cell Biol, 2000, 149: 1419-1432.
5Birchmeier C, Gherardi E. Developmental roles of HGF/SF and its receptor, the c-met tyrosine kinase. Trends Cell Biol, 1998, 8: 404-409.
6Vargas GA, Hoeflich A, Jehle PM. Hepatocyte growth factor in renal failure: Promise and reality. Kidney Int, 2000, 57: 1426-1436.
7Uehara Y, Minowa O, Mori C, et al. Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/ scatter factor. Nature, 1995,373: 702-705.
8Bohle A, Muller GA, Wehrmann M, et al. Pathogenesis of chronic renal failure in the primary glmerulopathies, renal vasculopathies, and chronic interstitial nephritides. Kidney Int, 1996, 49: 2.
9Ong AC, L.G Fine. Loss of glomerular function and tubulointerstitial fibrosis: cause or effect. Kidney Int, 1994, 45: 345-351.
10Eddy AA. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol, 1996,7: 2495-2508.
8Guo G, MorrisseyJ, McCracken R, et al. Role of TNFR1 and TNFR2 receptors in tubulointerstitial fibrosis of obstructive nephropathy. Am J Physiol, 1999,277 (5 pt 2): 766 - 772.
9Liu YH. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol, 2004, 15 ( 1 ): 1-12.
10Strutz F, Carone RL, Tomaszewski JE,et al. Transdifferentiation: a new concept in renal fibrogenesis. Am J Soc Nephrol, 1994,5 (10): 819 - 826.
